![]() |
市場調查報告書
商品編碼
2088873
短讀定序市場:2026-2032年全球市場預測(依產品類型、技術、讀取類型、通量、資料輸出及應用分類)Short-read Sequencing Market by Product, Technology, Read Type, Throughput, Data Output, Application - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,短讀定序市場將成長至 227.6 億美元,複合年成長率為 16.42%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 78.4億美元 |
| 預計年份:2026年 | 91.5億美元 |
| 預測年份 2032 | 227.6億美元 |
| 複合年成長率 (%) | 16.42% |
短讀定序仍然是次世代定序領域的領先技術,可為全基因測序、EXOME定序、RNA定序、宏基因總體基因體學、單細胞分析和標靶定序提供高通量和準確的讀取數據。
短讀定序的發展趨勢正從集中式、針對特定研究的定序轉向分散式、規範化和應用導向的工作流程。採購者越來越重視並評估每個樣本的總成本、樣品製備效率、處理時間、樣本處理能力、與資訊科學的兼容性以及分析有效性的依據。
人工智慧在短讀定序工作流程中發揮核心作用,涵蓋鹼基識別、變異檢測、品管、污染檢測、讀段比對支援、表現型解讀以及臨床報告優先排序等各個環節。同行評審的基準研究表明,結合特徵明確的資料集和檢驗的流程,使用深度學習的變異檢測器能夠顯著提升細胞株和體細胞變異的檢測性能。
在北美,強大的學術醫療中心、私人實驗室、公共衛生定序網路、美國國立衛生研究院 (NIH) 支持的基因組學計劃以及美國舉措管理局 (FDA) 批准的次世代定序診斷技術領先基因組學的普及。在歐洲,各國受益於國家基因組學計劃、符合 GDPR 的數據管理、生物樣本庫基礎設施以及公共衛生系統內臨床定序的擴展,儘管歐洲體外醫療設備法規 (IVDR) 仍在持續影響著人們對檢驗、文件記錄和上市後證據的期望。
七國集團(G7)持續制定臨床標準、報銷機制、公共衛生緊急準備以及短讀定序的大規模研究經費。同時,歐盟正透過《一般資料保護規範》(GDPR)、《體外診斷醫療器材法規》(IVDR)、健康資料管治和跨國研究合作等措施影響合規性。北約成員國也日益將基因組監測(包括病原體監測、疫情應變和彈性檢查室基礎設施)視為生物安全措施的一部分。
美國仍然是重要的創新中心,這得益於美國國立衛生研究院 (NIH) 的資助、CLIA 認證的檢查室、腫瘤檢測、罕見疾病項目、生物製藥行業的需求以及公共衛生領域的定序能力。加拿大正透過省級醫療保健系統、研究型醫院和國家基因組學研究經費推動基因組學的應用,而墨西哥則透過學術機構、腫瘤領域的需求以及在感染疾病的應用來擴大其應用範圍。巴西則憑藉其研究機構、公共衛生監測和癌症基因組學研究舉措,在拉丁美洲的定序領域處於領先地位。
產業領導者應使儀器藍圖與檢驗的臨床工作流程保持一致,降低高品質基因組或基因組檢測的成本,並提高樣本製備、檢體追蹤和污染控制的自動化程度。與醫院系統、參考實驗室、大學附屬醫院、公共衛生機構和生物製藥團隊夥伴關係,可以加速證據產生和工作流程部署。
本執行摘要是基於對同行評審的基因組學文獻、公共衛生定序計劃、監管指南、臨床實驗室標準、機構基因組學舉措和認可的科學資訊來源的二手研究。
由於其高通量、高準確性、生態系統成熟度、檢驗的工作流程以及在臨床診斷、群體基因組學、腫瘤學、感染疾病監測和生命科學研究等領域的廣泛應用,短讀定序將繼續成為可擴展基因組學的基礎。
The Short-read Sequencing Market is projected to grow by USD 22.76 billion at a CAGR of 16.42% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 7.84 billion |
| Estimated Year [2026] | USD 9.15 billion |
| Forecast Year [2032] | USD 22.76 billion |
| CAGR (%) | 16.42% |
Short-read sequencing remains the workhorse of next-generation sequencing because it delivers high-throughput, accurate reads for whole-genome sequencing, exome sequencing, RNA sequencing, metagenomics, single-cell assays, and targeted panels.
For platform, reagent, and consumables suppliers, demand is anchored in clinical genomics, oncology, inherited disease testing, infectious disease surveillance, agricultural genomics, and biopharma research, where reproducible chemistry, automation, quality controls, and validated workflows are essential purchasing criteria.
The short-read sequencing landscape is shifting from centralized, research-only sequencing toward distributed, regulated, and application-specific workflows. Buyers increasingly evaluate total cost per sample, library preparation efficiency, turnaround time, sample throughput, informatics compatibility, and evidence of analytical validity.
Competition is also broadening as high-throughput instruments, benchtop systems, patterned flow cells, multiplexed workflows, and integrated sample-to-report models reduce access barriers while raising expectations for service continuity, uptime, data quality, and supply assurance.
Artificial intelligence is becoming central to short-read sequencing workflows across base calling, variant calling, quality control, contamination detection, read alignment support, phenotype interpretation, and clinical report prioritization. Peer-reviewed benchmarking has shown that deep-learning variant callers can improve germline and somatic variant detection performance when paired with well-characterized datasets and validated pipelines.
For instrument and workflow leaders, AI shifts differentiation from hardware alone to combined chemistry, signal processing, cloud or on-premise bioinformatics, cybersecurity, auditability, and explainable analytics that can support regulated clinical, translational, and research use.
North America leads adoption through strong academic medical centers, commercial laboratories, public health sequencing networks, NIH-supported genomics initiatives, and FDA-recognized pathways for next-generation sequencing diagnostics. Europe benefits from national genomics programs, GDPR-governed data practices, biobank infrastructure, and expanding clinical sequencing under public health systems, while the European IVDR continues to influence validation, documentation, and post-market evidence expectations.
Asia-Pacific is scaling rapidly as China, Japan, South Korea, India, Australia, and ASEAN markets invest in precision medicine, pathogen surveillance, newborn and rare disease programs, cancer genomics, and population genomics. Latin America is showing rising demand led by Brazil and Mexico, where oncology diagnostics, infectious disease monitoring, and academic sequencing networks are expanding access. The Middle East is accelerating adoption through precision health strategies, national genome initiatives, and tertiary care investments, while Africa is strengthening sequencing capacity through infectious disease surveillance, antimicrobial resistance monitoring, and regional genomics training networks.
The G7 continues to shape clinical standards, reimbursement evidence, public health preparedness, and large-scale research funding for short-read sequencing, while the European Union influences compliance through GDPR, IVDR, health data governance, and cross-border research collaboration. NATO-aligned countries increasingly view genomic surveillance as part of biosecurity readiness, including pathogen monitoring, outbreak response, and resilient laboratory infrastructure.
BRICS nations are expanding domestic sequencing capacity, data sovereignty policies, biobank development, and population-scale research to reduce dependence on external infrastructure and strengthen local genomics ecosystems. ASEAN countries are investing in infectious disease genomics, cancer testing, and regional laboratory modernization, while GCC markets are advancing precision health, newborn screening, rare disease genomics, and national genome programs, creating demand for robust, scalable short-read sequencing platforms with local service, training, and informatics support.
The United States remains a major innovation hub, supported by NIH funding, CLIA-certified laboratories, oncology testing, rare disease programs, biopharma demand, and public health sequencing capacity. Canada advances adoption through provincial healthcare systems, research hospitals, and national genomics funding, while Mexico is expanding access through academic centers, oncology demand, and infectious disease applications. Brazil leads Latin American sequencing activity through research institutes, public health surveillance, and cancer genomics initiatives.
In Europe, the United Kingdom, Germany, France, Italy, and Spain advance short-read sequencing through public health systems, national genomics strategies, cancer and rare disease programs, and biobank-linked research, while Russia maintains research and public health sequencing capacity shaped by domestic procurement and localization priorities. In Asia-Pacific, China, Japan, South Korea, India, and Australia are expanding population genomics, clinical testing, reproductive health applications, agricultural genomics, and pathogen surveillance, with Australia also supported by strong translational research networks and national precision medicine initiatives.
Industry leaders should align instrument roadmaps with validated clinical workflows, reduce cost per high-quality genome or panel, and strengthen library preparation automation, sample tracking, and contamination control. Partnerships with hospital systems, reference laboratories, academic medical centers, public health agencies, and biopharma teams can accelerate evidence generation and workflow adoption.
Suppliers should also invest in AI-enabled quality metrics, transparent variant calling performance, cybersecurity, interoperability with laboratory information systems, flexible deployment models, and regional service networks to reduce downtime and support regulated use across research, clinical, and public health environments.
This executive summary is based on secondary research across peer-reviewed genomics literature, public health sequencing programs, regulatory guidance, clinical laboratory standards, institutional genomics initiatives, and recognized scientific sources.
Insights were triangulated by application area, region, customer type, technology adoption signals, workflow requirements, regulatory context, and public health use cases to identify evidence-backed trends shaping short-read sequencing demand and commercialization without relying on market sizing, market share, or forecasting assumptions.
Short-read sequencing continues to define scalable genomics because it combines throughput, accuracy, ecosystem maturity, validated workflows, and broad application coverage across clinical diagnostics, population genomics, oncology, infectious disease surveillance, and life science research.
The next phase of competition will depend on integrated platforms that combine sequencing chemistry, automation, AI analytics, regulatory readiness, data security, interoperability, and service reliability into dependable sample-to-insight workflows for laboratories worldwide.